Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.50 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14165710 | 1.00 | DRD2 (0.50) | DRD2CACNA1HSIGMAR1MEN1GAA | |
| SCHEMBL16208607 | 0.90 | DRD2 (0.50) | DRD2CACNA1HSIGMAR1MEN1GAA | |
| SCHEMBL21754610 | 0.88 | DRD2 (0.52) | DRD2CACNA1HSIGMAR1TDP1CD274 | |
| SCHEMBL22252842 | 0.88 | DRD2 (0.49) | DRD2CACNA1HSIGMAR1MEN1GAA | |
| SCHEMBL20411791 | 0.85 | DRD2 (0.47) | DRD2CACNA1HSIGMAR1MEN1KMT2A | |
| SCHEMBL31301242 | 0.84 | DRD2 (0.63) | DRD2CACNA1HSIGMAR1MEN1GAA | |
| SCHEMBL20411793 | 0.84 | DRD2 (0.50) | DRD2CACNA1HSIGMAR1TDP1CD274 | |
| SCHEMBL25716981 | 0.83 | DRD2 (0.54) | DRD2CACNA1HSIGMAR1TDP1CD274 | |
| SCHEMBL13202614 | 0.80 | DRD2 (0.59) | DRD2CACNA1HSIGMAR1MEN1GAA | |
| SCHEMBL31110037 | 0.79 | DRD2 (0.55) | DRD2CACNA1HSIGMAR1MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340560-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12187687-B2 | Compositions and uses thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240270700-A1 | COMPOSITIONS AND USES THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2024-08-15 | — | — | US | disclosed |
| US-20240254128-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2024-08-01 | — | — | US | disclosed |
| US-20230013862-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2023-01-19 | — | — | US | disclosed |
| US-20230013862-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2023-01-19 | — | — | US | disclosed |
| EP-4056562-A1 | HETEROCYCLIC INHIBITORS OF BRUTON'S TYROSINE KINASE | Merck Patent GmbH (DE) | 2022-09-14 | — | — | EP | disclosed |
| US-11142528-B2 | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators | BEIGENE SWITZERLAND GMBH (CH) | 2021-10-12 | — | — | US | disclosed |
| US-11142528-B2 | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators | BEIGENE SWITZERLAND GMBH (CH) | 2021-10-12 | — | — | US | disclosed |
| US-20200231551-A1 | COMPOSITIONS AND USES THEREOF | UNIVERSITY OF VIRGINIA | 2020-07-23 | — | — | US | disclosed |
| WO-2015017502-A1 | PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2015-02-05 | — | — | WO | disclosed |
| WO-2014173289-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | BEIGENE, LTD. (KY) | 2014-10-30 | — | — | WO | disclosed |
| US-20140162983-A1 | Compositions and Methods for the Production of Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | MERCK PATENT GMBH (DE) | 2014-06-12 | — | — | US | disclosed |
| EP-2718270-A2 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | Merck Patent GmbH (DE) | 2014-04-16 | — | — | EP | disclosed |
| US-20130225812-A1 | BRUTON'S TYROSINIE KINASE ACTIVITY PROBE AND METHOD OF USING | PHARMACYCLICS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| EP-2089391-B1 | BRUTON'S TYROSINE KINASE ACTIVITY PROBE AND METHOD OF USING | PHARMACYCLICS INC (US) | 2013-01-16 | — | — | EP | disclosed |
| WO-2012170976-A2 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | MERCK PATENT GMBH (DE) | 2012-12-13 | — | — | WO | disclosed |
| US-20080214501-A1 | Bruton's tyrosine kinase (Btk) activity probe comprising a Btk inhibitor moiety, a reporter moiety, and a linker moiety that links the inhibitor moiety to the reporter moiety; probes are used to characterize and develop Btk-selective inhibitors intended for therapeutic use | PHARMACYCLICS, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080214501-A1 | Bruton's tyrosine kinase (Btk) activity probe comprising a Btk inhibitor moiety, a reporter moiety, and a linker moiety that links the inhibitor moiety to the reporter moiety; probes are used to characterize and develop Btk-selective inhibitors intended for therapeutic use | PHARMACYCLICS, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| WO-2008054827-A2 | BRUTON'S TYROSINE KINASE ACTIVITY PROBE AND METHOD OF USING | PHARMACYCLICS, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270700-A1 | COMPOSITIONS AND USES THEREOF | CYP11B2, NQO1, CYP11B1 | DRD2 4140/4885CACNA1H 4589/4885SIGMAR1 1168/4885 |
| US-20130225812-A1 | BRUTON'S TYROSINIE KINASE ACTIVITY PROBE AND METHOD OF USING | BTK, SYK, LYN | DRD2 4521/4885CACNA1H 3732/4885SIGMAR1 4400/4885 |
| US-20240254128-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | DRD2 4861/4885CACNA1H 3300/4885SIGMAR1 3653/4885 |
| US-20200231551-A1 | COMPOSITIONS AND USES THEREOF | CYP11B2, NQO1, CYP11B1 | DRD2 4140/4885CACNA1H 4589/4885SIGMAR1 1168/4885 |
| US-20080214501-A1 | Bruton's tyrosine kinase (Btk) activity probe comprising a Btk inhibitor moiety, a reporter moiety, and a linker moiety that links the inhibitor moiety to the reporter moiety; probes are used to characterize and develop Btk-selective inhibitors intended for therapeutic use | BTK, SYK, LYN | DRD2 4210/4885CACNA1H 4474/4885SIGMAR1 4636/4885 |
| US-12187687-B2 | Compositions and uses thereof | CYP11B2, CYP11B1, NQO1 | DRD2 4180/4885CACNA1H 4521/4885SIGMAR1 899/4885 |
| US-20140162983-A1 | Compositions and Methods for the Production of Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | BTK, SYK, LCK | DRD2 4507/4885CACNA1H 4742/4885SIGMAR1 4714/4885 |
| US-11142528-B2 | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators | BTK, LCK, SYK | DRD2 4861/4885CACNA1H 3300/4885SIGMAR1 3653/4885 |
| US-20230013862-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | DRD2 4861/4885CACNA1H 3300/4885SIGMAR1 3653/4885 |
| US-20250340560-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | DRD2 4861/4885CACNA1H 3300/4885SIGMAR1 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.